Cyfuse Biomedical KKTSE:4892 +0.39%54 Piotroski F-Score is 3 as of Jun. 28, 2026, which is at its 10-year median of 3.00. GuruFocus rates TSE:4892 with a GF Score™ of 54/100 and a GF Value™ of 円1,962.33 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 978 Drug Manufacturers companies, Cyfuse Biomedical KK ranks worse than 78.12% on this metric.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Cyfuse Biomedical KK has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Cyfuse Biomedical KK's Piotroski F-Score or its related term are showing as below:
TSE:4892'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 3 Max: 3
Current: 3
During the past 6 years, the highest Piotroski F-Score of Cyfuse Biomedical KK was 3. The lowest was 2. And the median was 3.
Cyfuse Biomedical KK (TSE:4892) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Cyfuse Biomedical KK Piotroski F-Score Related Terms
Cyfuse Biomedical KK Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyfuse Biomedical KK Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Cyfuse Biomedical KK's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Cyfuse Biomedical KK's current Net Income (TTM) was -763.84.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Cyfuse Biomedical KK's current Cash Flow from Operations (TTM) was -534.79.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Cyfuse Biomedical KK's return on assets of this year was -0.21712416. Cyfuse Biomedical KK's return on assets of last year was -0.20694603.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Cyfuse Biomedical KK's gearing of this year was 0.16503951. Cyfuse Biomedical KK's gearing of last year was 0.08457469.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Cyfuse Biomedical KK's current ratio of this year was 4.54293048. Cyfuse Biomedical KK's current ratio of last year was 4.99558739.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Cyfuse Biomedical KK's number of shares in issue this year was 8.802. Cyfuse Biomedical KK's number of shares in issue last year was 8.051.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Cyfuse Biomedical KK's gross margin of this year was 0.49304975. Cyfuse Biomedical KK's gross margin of last year was 0.30946259.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Cyfuse Biomedical KK's asset turnover of this year was 0.06566201. Cyfuse Biomedical KK's asset turnover of last year was 0.01291779.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
0
+
0
+
0
+
1
+
1
=
3
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Cyfuse Biomedical KK has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
Cyfuse Biomedical KK (TSE:4892) has a Piotroski F-Score of 3 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Cyfuse Biomedical KK and its competitors. This is near median its historical median of 3.00. Over the past decade, Cyfuse Biomedical KK's Piotroski F-Score has ranged from 2.00 to 3.00. According to the industry distribution chart, Cyfuse Biomedical KK ranks #764 out of 978 companies in the Drug Manufacturers industry, placing it in the top 78.1%.
Is Cyfuse Biomedical KK's Piotroski F-Score too high?
Cyfuse Biomedical KK's current Piotroski F-Score of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 3.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Cyfuse Biomedical KK's value of 3 is 40% below this industry median. Based on the distribution chart, Cyfuse Biomedical KK ranks #764 out of 978 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cyfuse Biomedical KK has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #764 out of 978 companies for Piotroski F-Score. This places Cyfuse Biomedical KK in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Cyfuse Biomedical KK's value of 3 is 40% below this benchmark. Historically, Cyfuse Biomedical KK's own Piotroski F-Score has ranged from 2.00 to 3.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, Cyfuse Biomedical KK has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyfuse Biomedical KK's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Cyfuse Biomedical KK and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current Piotroski F-Score is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,962.33, compared to a current price of 円520.00 — trading 73.5% below its estimated fair value. The current Piotroski F-Score is 3, which is near median its 10-year median of 3.00 and 40% below the Drug Manufacturers industry median of 5.00. Cyfuse Biomedical KK's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current Piotroski F-Score is 3 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円520.00 is trading 73.5% below its estimated GF Value™ of 円1,962.33.
GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.
Key valuation signals for TSE:4892:
Piotroski F-Score: 3 (near median its 10-year median of 3.00)
GF Value™: 円1,962.33 vs. price of 円520.00 (73.5% below fair value)
Industry Position: 40% below the Drug Manufacturers median (#764 of 978)
No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
54GF Score
Get the complete analysis for TSE:4892
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4892 has been successfully added to your 
